Ontology highlight
ABSTRACT:
SUBMITTER: Antelope O
PROVIDER: S-EPMC6803074 | biostudies-literature | 2019 Sep
REPOSITORIES: biostudies-literature
Antelope Orlando O Vellore Nadeem A NA Pomicter Anthony D AD Patel Ami B AB Van Scoyk Alexandria A Clair Phillip M PM Deininger Michael W MW O'Hare Thomas T
Experimental hematology 20190904
BCR-ABL1 tyrosine kinase inhibitors (TKIs) are the cornerstone of treatment in chronic myeloid leukemia. Although there are now four TKIs approved for use in the front-line setting, acquired TKI resistance via secondary kinase domain mutations remains a problem for patients. K0706 is a novel BCR-ABL1 TKI currently under clinical investigation with structural elements similar to those of ponatinib and dasatinib. In this article, we functionally characterize the anti-leukemic activity of K0706 usi ...[more]